Literature DB >> 7218450

Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade.

B B Cantrell, D P DeKlerk, J C Eggleston, J K Boitnott, P C Walsh.   

Abstract

To determine the pathologic factors useful in predicting prognosis in patients with stage A prostatic cancer we studied 117 patients followed for 2 to 15 years. Since no patient was treated until progression of disease occurred we were able to correlate pathologic findings with the natural history of the disease in an untreated population of patients. In 14 patients (12 per cent) extensive local (2) or metastatic (12) disease developed. Because 12 of the 14 patients had progression of the disease within 4 years we thought than an analysis of all patients followed for 4 years would be useful. Extent and grade of disease were the 2 factors that most accurately predicted progression. No patient with a low grade lesion (Hopkins grade 1 or Gleason total score 2 to 4) had progression and only 2 per cent of patients with less than 5 per cent cancer had progression. These patients were classified as stage A1 and 60 per cent of all patients were in this category. We believe that these patients require no further therapy. Of the patients with more than 5 per cent cancer 32 per cent had progression and 17 per cent of the patients with either Hopkins grade 2 to 3 disease or Gleason total score more than 4 had progression. These patients were classified as stage A2 and their optimal management remains to be determined.

Entities:  

Mesh:

Year:  1981        PMID: 7218450     DOI: 10.1016/s0022-5347(17)55092-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  A molecular signature predictive of indolent prostate cancer.

Authors:  Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Sci Transl Med       Date:  2013-09-11       Impact factor: 17.956

2.  Incidental prostatic carcinoma: morphometry correlated with histological grade.

Authors:  R Yatani; T Shiraishi; K Akazaki; T Hayashi; L K Heilbrun; G N Stemmermann
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

Review 3.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

Review 4.  Prostate cancer: 2. Natural history.

Authors:  R K Nam; M A Jewett; M D Krahn
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

5.  Incidental versus manifest prostatic carcinoma.

Authors:  P E Jørgensen; N Weis; E Bruun
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

6.  Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status?

Authors:  K Kunimi; T Amano; S W Lee; H Fuse; T Uchibayashi; K Miyazaki; M Ohkawa
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 7.  ACP Broadsheet No 146: August 1995. Macroscopic examination of prostatic specimens.

Authors:  P Harnden; M C Parkinson
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

8.  Early (stage A) prostatic cancer. VI. A critical look at the follow-up.

Authors:  S Battaglia; G Barbolini; A R Botticelli; G Berri; E Nigrisoli
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

9.  An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney
Journal:  Mod Pathol       Date:  2010-09-10       Impact factor: 7.842

10.  Prostate cancer with bladder neck involvement: pathologic findings with application of a new practical method for tumor extent evaluation and recurrence-free survival after radical prostatectomy.

Authors:  Athanase Billis; Leandro L L Freitas; Luis A Magna; Adil B Samara; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.